Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
peer reviewed ; BACKGROUND: Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban. METHODS: With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 mL/min, weight ≤60 kg, and/or use of strong p-glycoprotein inhibitors)... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journal article |
Erscheinungsdatum: | 2021 |
Schlagwörter: | Anticoagulants / Factor Xa Inhibitors / Pyridines / Thiazoles / NDU3J18APO (edoxaban) / Aged / Atrial Fibrillation/complications/drug therapy/epidemiology / Belgium/epidemiology / Europe/epidemiology / Factor Xa Inhibitors/therapeutic use / Humans / Netherlands/epidemiology / Prospective Studies / Pyridines/therapeutic use / Thiazoles/therapeutic use / Treatment Outcome / clinical trial / phase IV / haemorrhage / off-label use / stroke / thromboembolism / Human health sciences / Cardiovascular & respiratory systems / Sciences de la santé humaine / Systèmes cardiovasculaire & respiratoire |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27591957 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://orbi.uliege.be/handle/2268/290919 |